Citas bibligráficas
Abanto, G., (2020). Efectos del sulfato de magnesio en neonatos de madres con enfermedad hipertensiva del embarazo, Hospital III de Iquitos, 2018 - 2019 [Universidad Nacional de la Amazonía Peruana]. http://repositorio.unapiquitos.edu.pe/handle/20.500.12737/7038
Abanto, G., Efectos del sulfato de magnesio en neonatos de madres con enfermedad hipertensiva del embarazo, Hospital III de Iquitos, 2018 - 2019 []. : Universidad Nacional de la Amazonía Peruana; 2020. http://repositorio.unapiquitos.edu.pe/handle/20.500.12737/7038
@misc{sunedu/3115367,
title = "Efectos del sulfato de magnesio en neonatos de madres con enfermedad hipertensiva del embarazo, Hospital III de Iquitos, 2018 - 2019",
author = "Abanto Rodríguez, Guadalupe Madelein",
publisher = "Universidad Nacional de la Amazonía Peruana",
year = "2020"
}
Objective: To demonstrate whether the use of magnesium sulfate during maternal treatment of hypertensive disease of pregnancy is associated with the presence of adverse events such as negative clinical signs during birth (Prematurity, low Apgar, hypotonia and meconium amniotic fluid), and the need of hospital support (need for admission to the NICU, need for mechanical ventilation and longer hospital stay) in neonates treated at a Third Level Hospital in Iquitos during the years 2018 to 2019. Methodology: This research was observational, analytical and retrospective. There were a total of 776 patients with severe Preeclampsia and / or Eclampsia; According to the sample size formula, the sample consisted of 260 neonates. For the bivariate analysis and to calculate the association of variables, it was performed through the Chi square calculation with a statistical significance of 5% (p <0.05). The multivariate analysis was performed to identify confounding variables, taking as a criterion the association in the bi-varied analysis (Chi2 and significant p). Results: Low Apgar (Chi2 = 13.308, p = 0.000) and Prematurity (Chi2 = 5.834, p = 0.016) were statistically significant associated with fetal exposure to magnesium sulfate; however, hypotonia, meconium amniotic fluid, the need for admission to the NICU, the need for mechanical ventilation, and prolonged hospital stay were not associated. The multivariate analysis was able to demonstrate that exposure to magnesium sulfate reduces the risk of low apgar by 77.4% (OR = 0.226; CI: 0.08 - 0.63; p = 0.005); and prematurity in 54.2% (OR = 0.458; CI: 0.241 - 0.87; p = 0.017). Conclusion: Fetal exposure to magnesium sulfate was positively associated with some neonatal adverse events, reducing the risk of low Apgar and Prematurity.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons